Compositions and methods used for identifying factors required for the agglomeration of proteins
OwnerAbraham Grossmaninventor
Life of this patent
Estimating the term…
Abstract
Described herein are compositions and methods for identifying cellular factors involved in protein agglomeration. One such factor is a nucleic acid component. Another factor is a cellular macromolecular co-binding component. The presence of certain NAs and co-binding factors facilitate the agglomeration of certain proteins. The compositions and methods described herein are employed to identify this factors involved in the protein agglomeration process. Moreover, methods for assessing the efficacy of a pharmaceutical agent in protecting prion proteins is also described herein.
Claims33
A method of identifying the presence or absence of an agglomeration complex from a sample matrix obtained from an individual comprising the following steps:
- (a) forming an admixture of said sample matrix with one or more nucleic acids, wherein said one or more nucleic acids are obtained from a nucleotide antibody library;
- (b) incubating said admixture of step (a) under conditions suitable to form at least one agglomeration complex, wherein said agglomeration complex is represented by the following formula:
- [AxByCz]
- wherein A represents a protein and x is an integer having a value from one to infinity, B is a cellular binding cofactor, wherein said binding cofactor participates in the formation of the complex, and y is an integer having a value from 1 to infinity, and C is a nucleic acid selected from said library of nucleic acid antibodies and z is an integer having a value from 1 to infinity, wherein at least one of the groups consisting of A and B are present in said sample matrix, and the complex represented in brackets does not imply any order in A, B, or C, and A, B and C form an agglomeration complex through non-covalent bonds;
- (c) detecting said agglomeration complex.
A composition associated with an agglomeration complex, wherein said agglomeration complex is represented by the following formula:
- [AxByCz]
- wherein A represents a protein and x is an integer having a value from one to infinity, B is a cellular binding cofactor, wherein said binding cofactor participates in the formation of the complex through non-covalent interactions with macromolecules, and y is an integer having a value from 1 to infinity, and C is a nucleic acid selected from a library of nucleic acid antibodies and z is an integer having a value from 1 to infinity, wherein at least one of the groups consisting of A and B are present in said sample matrix, and wherein the complex represented in brackets does not imply any order in A, B, or C, and A, B and C form a complex through non-covalent bonds and non hybridization affinity.
A method for examining the efficacy of a pharmaceutical agent to protect prion protein against protease K digestion, comprising the following steps:
- (a) forming an admixture under having
- (i) one or more cellular binding factors;
- (ii) one or more nucleic acid antibodies, wherein said one or more nucleic acids antibodies are obtained from a nucleotide antibody library;
- (iii) one or more prion proteins;
- and
- (iv) said pharmaceutical agent;
- (b) adding to said admixture of step (a) protease K under conditions suitable
- for protease digestion of said prion protein;
- (c) detecting the presence of said prion protein of step (a), whereby the presence of said prion protein is indicative of a pharmaceutical agent that is effective in protecting said prion protein against protease digestion by protease K.
A kit for determining whether a test agent can inhibit protein agglomeration, comprising:
- (a) a NA antibody;
- (b) a CBF;
- and
- (c) a protein.
Dependencies are inferred from the claim text.